T he survival rates of pediatric patients with hematological malignancies are improving year by year due to advances in chemotherapy and the spread of hematopoietic stem cell transplantation (HSCT). In contrast, the incidence of severe infectious diseases, especially fungal infections, is increasing. 1 Recently, the concept of febrile neutropenia (FN) has spread, to encourage prompt treatment of patients with neutropenia and febrile conditions. Many diseases, such as bacterial, fungal, and viral infections and other febrile conditions, are included under the term FN. One report revealed that fungal infection was seen in 40% of patients with FN. 2 In contrast, Bakhshi et al 3 reported that 22 of 222 FN episodes were fungal infection in childhood acute lymphoblastic leukemia. FN with infection is a medical emergency that requires rapid diagnosis and prompt intervention. The localizing signs and symptoms of infection are often minimal or absent and the progression of infection can be rapid in FN patients. 4 If first-line antibiotics are not effective, many physicians change the therapy to other antibiotics or add another antibiotic or antifungal agent. Invasive fungal infections (IFI) are a major cause of infection-related mortality during the induction of chemotherapy in patients with hematological malignancies, highlighting the important role of antifungal agents.
Micafungin (MCFG) is an echinocandin antifungal agent that inhibits the synthesis of 1,3-b-D-glucan, a critical component of the fungal cell wall, and shows excellent antifungal activity against a broad range of Candida species, including azole-resistant strains, and Aspergillus species. 5 MCFG has been shown to be an effective and safe treatment for IFI in several clinical trials. [5] [6] [7] [8] However, there are limited data on the efficacy and safety of MCFG for suspected IFI, especially for FN in patients with hematological disorders. [9] [10] [11] [12] [13] [14] Recently, Walsh and colleagues [15] [16] [17] established efficacy criteria for empiric antifungal therapy. These criteria were created based on the following 5 composite end points: successful treatment of baseline fungal infection, absence of breakthrough fungal infection, survival for >7 days after study therapy, no study therapy discontinued prematurely because of toxicity or lack of efficacy, and resolution of fever during neutropenia. Treatment was considered successful if all 5 criteria were met. Using these criteria, they reported efficacies of caspofungin and liposomal amphotericin in pediatric patients of 48.2% and 46.2%, respectively. 17 Although Yamaguchi et al 18 recently reported the efficacy of MCFG for FN in adult patients by use of these criteria, little is known about the efficacy of MCFG in pediatric patients. Herein, we investigated the efficacy using the criteria of Walsh and colleagues, [15] [16] [17] and side effects of MCFG for FN in pediatric patients with hematological diseases.
PATIENTS AND METHODS

Patient Eligibility
From January 2006 to December 2010, we enrolled patients under the age of 16 years with hematological diseases and solid tumors who had been treated with chemotherapy or received stem cell transplantation at the pediatric units of Sapporo Hokuyu Hospital, Hokkaido University Hospital, Sapporo Medical University Hospital, Asahikawa Medical College Hospital, Hokkaido Cancer Center, and Hokkaido Medical Center for Child Health and Rehabilitation, and who satisfied the criteria shown below: patients with FN who were resistant to broad-spectrum antibiotics over 5 days were registered. The exclusion criteria decided on were: (1) patients medicated with other antifungal drug injections; (2) patients in whom the tumor was believed to be the cause of fever; (3) patients with IFI due to cryptococcus, zygomycosis, and trichosporon, which are unresponsive to MCFG; (4) patients with hypersensitivity to MCFG; (5) patients in whom removal of the central venous catheter was effective in treating the fever, and in whom it was difficult to decide the efficacy of MCFG; and (6) patients who declined participation. Patients with repeated episodes were reregistered separately each time.
Study Design
A complete history was obtained, and physical examination, laboratory tests, and a routine computed tomography of the chest and abdomen were performed on all patients. After initial evaluation, the patients were assigned to receive MCFG (1 to 3 mg/kg/d) as a drip infusion for 1 hour once a day. If MCFG was not effective at 5 days after initiation, the attending physician could increase the dose of MCFG in patients up to 6 mg/kg/d (maximum 300 mg). Treatment was continued until completion of the appropriate therapeutic course for the defined clinical or microbiological infection.
Evaluation criteria of Walsh and colleagues [15] [16] [17] were used in addition to body temperature and value of Creactive protein (CRP). Overall response was defined as favorable if all of the protocol-defined composite end points were met. Addition of another antifungal agent to MCFG and change to another drug were considered as indicative of ineffectiveness of therapy or impossibility of evaluation. Adverse effects were evaluated using Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
This research was approved by the Institutional Review Boards of each of the participating hospitals. Informed consent was obtained from all patients or patients' parents.
Statistical Analysis
Differences in body temperature and CRP on 3 occasions (before MCFG, the last day under 500/mL of neutrophil, and on the last day of MCFG therapy) were analyzed using the Fisher exact test and the Mann-Whitney U test. Statistical analyses were performed using Dr SPSS II for Windows (release 11.0.1J, SPSS Japan Inc.).
RESULTS
Twenty-five patients and 30 febrile episodes were enrolled in the study (Table 1) . Fourteen of the episodes were in boys and 16 in girls. Median patient age was 5 years (range, 0 to 15 y). Thirteen episodes (13 patients) had acute lymphoblastic leukemia, 9 (5 patients) had acute myelogenous leukemia, and 8 (7 patients) episodes had other diseases, including 2 each with juvenile myelomonocytic leukemia, hepatoblastoma, and retinoblastoma. All of the episodes occurred after chemotherapy. All patients were administered antibiotics with MCFG. In 7 of 30 cases, bacteria were positive from blood culture. Bacteremia existed before administration of MCFG in 4 patients (Streptococcus capitis, Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus species) and after administration (Staphylococcus epidermidis in 2 cases, coagulase-negative Staphylococcus). Fungus was not detected. The initial doses and duration of MCFG administered were 3.0 mg/kg/d (median; range, 1.8 to 5.2 mg/kg/d) and 13.5 days (median; range, 6 to 47 d), respectively.
Body temperatures on the last day of neutropenia during administration of MCFG and on the last day of therapy with MCFG were significantly lower than on the day MCFG therapy was started (Fig. 1) . Similarly, CRP values significantly decreased after administration of MCFG. Using the FN evaluation of Walsh and colleagues, therapy was effective in 17 of 30 patients (Table 2) . Specifically, 100% of the episodes did not have fungal breakthrough, 90.0% of episodes lived for over 7 days after administration of MCFG, discontinuation of administration due to side effects or noneffectiveness was not observed in 93.3% of episodes, and 66.7% of episodes had resolution of fever during neutropenia.
In terms of adverse effects, liver dysfunction was seen in 2 of the 30 cases. However, the grade of liver dysfunction by CTCAE was 2 and 3, respectively. The administered doses and durations of MCFG in these 2 patients were 3.1 and 3.9 mg/kg, and 8 and 9 days, respectively.
DISCUSSION
The incidence of IFI is increasing. Although amphotericin B and azole antifungals have been the mainstay of antifungal therapy so far, the high incidence of infusion-related toxicity and nephrotoxicity with amphotericin B 19 and the emergence of fluconazole-resistant strains of Candida glabrata 20 have stimulated the search for alternatives. Moreover, because azole antifungal agents are known to inhibit cytochrome P450 3A (CYP3A) enzymes, 21 physicians must pay attention to the other drugs being used by their patients when starting azole therapy.
MCFG is an echinocandin antifungal agent, that inhibits the synthesis of 1,3-b-D-glucan in the fungal cell wall, and shows excellent antifungal activity against a broad range of Candida and Aspergillus species. 5 Its favorable safety profile has made it an attractive option in the treatment of invasive candida and aspergillus infections. In addition, MCFG does not seem to cause clinically significant interactions with drugs that are metabolized by CYPs. 5 Studies on MCFG established its utility in esophageal candidiasis 22 and in candida prophylaxis in HSCT recipients. 23 Its place in the treatment of aspergillus is evolving, with some previous case reports showing good activity and primary studies demonstrating safety of the drug. 24 , 25 Denning et al 26 conducted a multinational, noncomparative, open-label trial to examine the efficacy of MCFG in proven or probable pulmonary aspergillosis in adult and pediatric patient populations, including HSCT, graft versus host disease, and patients who received chemotherapy for hematological malignancy. Those treated primarily with MCFG alone showed up to 50% favorable responses, and the salvage therapy group showed 40.9% response. Although the numbers were small, the study demonstrated the efficacy of MCFG in invasive pulmonary aspergillosis, whether primary or salvage.
However, reports about MCFG for the early treatment of FN, especially in pediatric patients, are relatively few. [9] [10] [11] [12] [13] [14] In adults, Toubai et al 9 and Goto et al 11 reported 73.9% and 70% efficacy of MCFG in FN patients with hematological malignancies, respectively. As it is difficult to judge the distinct effects of antifungal drugs or recovery of neutropenia, judgment of effectiveness with antifungal drugs for FN is very difficult. Recently, Walsh and colleagues [15] [16] [17] used efficacy criteria for empiric antifungal therapy; these criteria were created based on a 5-part composite end point, and treatment was considered successful if all 5 criteria were met. Using these criteria, they reported efficacies of caspofungin and liposomal amphotericin in pediatric patients of 48.2% and 46.2%, respectively. 17 In our study, using these criteria, MCFG was effective in 56.7% of episodes, which is an excellent result. Adverse effects in the form of mild liver dysfunction were seen in only 2 patients in our study, indicating the safety of MCFG therapy. The dose of MCFG administered in our study varied widely from 1 to 6 mg/kg. We analyzed the efficacy of different doses of MCFG, but did not find any difference in the dose-related efficacy of MCFG in each group and in all the patients considered together. The minimum MCFG dose in our patients was 1.8 mg/kg, and many patients were administrated over 2.5 mg/kg. This, The primary efficacy end point was a favorable overall response, as determined by a 5-component end point that has been used in previous studies of empirical antifungal therapy (Walsh and colleagues [14] [15] [16] ). *Salvage treatment for the patients who discontinued the study therapy was the addition of voriconazole to MCFG or the change to liposomal amphotericin.
FN indicates febrile neutropenia; MCFG, micafungin.
however, is not sufficient evidence to show that low doses of MCFG may be adequate to produce therapeutic effect. The possibility that the use of MCFG may result in the growth of resistant fungi, such as Trichosporon species, has been reported. 27, 28 However, there was no breakthrough fungal disease in our patients.
In conclusion, MCFG is an effective and safe antifungal drug for the treatment of FN in children. Physicians should administer MCFG early during the illness, when first-line antibiotics are ineffective against FN.
